1-3 of 3
Klaus Pantel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

HER2(-Low) Expression on Circulating Tumor Cells and Corresponding Metastatic Tissue in Metastatic Breast Cancer

Available to Purchase
Subject Area:
Article Collection: Liquid Biopsy in Diagnosis and Treatment Monitoring of Solid Tumors , Oncology
Lara M. Tretschock, Hannah Clemente, Katharina Smetanay, Carlo Fremd, Verena Thewes, Kathrin Haßdenteufel, Anna S. Scholz, Klaus Pantel, Sabine Riethdorf, Andreas Trumpp, Andreas Schneeweiss, Laura Michel, Thomas M. Deutsch
Journal: Oncology Research and Treatment
Oncol Res Treat (2025) 48 (4): 161–173.
https://doi.org/10.1159/000542830
Published Online: 28 November 2024
View article titled, HER2(-Low) Expression on Circulating Tumor Cells and Corresponding Metastatic Tissue in Metastatic Breast Cancer
Open the PDF for HER2(-Low) Expression on Circulating Tumor Cells and Corresponding Metastatic Tissue in Metastatic Breast Cancer in another window
Journal Articles

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

Available to Purchase
Subject Area:
Oncology
Fabienne Schochter, Brigitte Rack, Marie Tzschaschel, Arkadius Polasik, Ulrich Andergassen, Elisabeth Trapp, Marianna Alunni-Fabbroni, Andreas Schneeweiss, Volkmar Müller, Klaus Pantel, Jörg Gade, Ralf Lorenz, Mahdi Rezai, Hans Tesch, Ulrike Soeling, Tanja Fehm, Sven Mahner, Christian Schindlbeck, Werner Lichtenegger, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Thomas W.P. Friedl, on behalf of the SUCCESS Study Group
Journal: Oncology Research and Treatment
Oncol Res Treat (2018) 41 (3): 93–98.
https://doi.org/10.1159/000485566
Published Online: 27 February 2018
View article titled, Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
Open the PDF for Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study in another window
Journal Articles

Liquid Biopsy: Current Status and Future Perspectives

Available to Purchase
Subject Area:
Topic Article Package: Cytology , Focus Article , Oncology
Sonja Mader, Klaus Pantel
Journal: Oncology Research and Treatment
Oncol Res Treat (2017) 40 (7-8): 404–408.
https://doi.org/10.1159/000478018
Published Online: 13 July 2017
View article titled, Liquid Biopsy: Current Status and Future Perspectives
Open the PDF for Liquid Biopsy: Current Status and Future Perspectives in another window